	US 12,435,110 B2
	Adenosomes
Jeroen De Vrij, Leidschendam (NL)
Assigned to Erasmus University Medical Center Rotterdam, Rotterdam (NL)
Appl. No. 17/274,891
Filed by Erasmus University Medical Center Rotterdam, Rotterdam (NL)
PCT Filed Sep. 17, 2019, PCT No. PCT/NL2019/050611 § 371(c)(1), (2) Date Mar. 10, 2021, PCT Pub. No. WO2020/060400, PCT Pub. Date Mar. 26, 2020.
Claims priority of application No. 2021648 (NL), filed on Sep. 17, 2018.
Prior Publication US 2022/0056081 A1, Feb. 24, 2022
Int. Cl. A61K 35/761 (2015.01); C07K 14/005 (2006.01); C12N 15/86 (2006.01); C12N 15/88 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 35/761 (2013.01); C12N 15/86 (2013.01); C12N 15/88 (2013.01); C07K 2319/60 (2013.01); C12N 2710/10322 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/10345 (2013.01); C12N 2710/10362 (2013.01); C12N 2810/405 (2013.01)]

14 Claims

1. Cellular vesicle comprising a recombinant adenoviral nucleic acid, wherein the recombinant adenoviral nucleic acid comprises a mutation in the early genes, wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter.